Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol.
Intrauterine diethylstilbestrol (DES) exposure is associated with an increased risk for the development of clear cell adenocarcinoma (CCA) of the vagina and cervix. The age of the DES-exposed patients has varied from 7 to 34 years with the highest frequency from 14 to 22 years. The risk among the exposed is small and is on the order of 1 per 1,000. Factors that may increase the risk are maternal history of prior miscarriage, exposure to DES in early gestation, a fall season of birth, and prematurity. Pregnancy does not appear to influence adversely the tumor characteristics or prognosis of patients who have developed these malignancies. Criteria for appropriate local therapy of small clear cell adenocarcinomas of the vagina are presented. Recurrent CCA has been observed as long as 20 years after primary therapy emphasizing the importance of prolonged follow-up.
Herbst
A L
AL
Department of Obstetrics and Gynecology, University of Chicago, IL.
Anderson
D
D
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D000293:Adolescent; D000328:Adult; D002648:Child; D004054:Diethylstilbestrol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D014625:Vaginal Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy
D004054:Diethylstilbestrol